Accretion Nutraveda Ltd IPO
Pharmaceuticals
Price Band
₹122 – ₹129
Lot Size
1000
Minimum Bid Quantity
2000
Minimum Investment
₹258000
Issue Size
₹24.77Cr
Opens
2026-01-28
Closes
2026-01-30
Listing
04-02-2026
Subscription Status
Qualified Institutional Buyers
1.01 x
Non-Institutional Investor
1.8 x
Retail Individual Investor
2.19 x
Total
1.77 x
IPO Details
Issue Type
FP
Face Value
₹10
Tick Size
1
ISIN
INE1KVQ01019
Pre-Apply Available
No
Daily Bidding Time
10:00:00 - 17:00:00
About the Company
Accretion Nutraveda Limited manufactures Ayurvedic and nutraceutical products and functions as a contract development and manufacturing organisation, serving domestic and export markets. It makes tablets, capsules, oral liquids, oral powders, external preparations, and oils. Tablets include film-coated and chewable varieties used in liver care, gynaecological care, bone and joint health, and respiratory support. Capsules include hard gelatin and HPMC formats for liver detoxification, women’s health, and cognitive support. Oral liquids include syrups, suspensions, and tonics for paediatric and geriatric use. It also produces churan powders, medicated Ayurvedic oils, and external balms, ointments, creams, and gels for pain relief, skin care, and hair care. The company runs a leased, two-floor manufacturing facility with 13 HEPA-filter air handling units and segregated processing and dispensing areas to limit cross-contamination.
Pros
- • Accretion Nutraveda Limited claims to have a product portfolio of over 72 formulations across Ayurvedic and nutraceutical segments. Its manufacturing capabilities span tablets, capsules, oral liquids, churans, oils, and multiple external preparations, covering therapeutic and wellness-focused applications. This range allows it to cater to varied formulation and dosage requirements under a single manufacturing setup.
- • The company’s manufacturing facility is stated to be WHO-GMP approved and certified under ISO 9001:2015 for its quality management systems and ISO 45001:2018 for occupational health and safety.
- • The company claims to have built ongoing relationships with clients and suppliers, overseen directly by its promoters. These relationships support the sourcing of raw materials, distribution activities, and operational continuity. Management involvement in these engagements is presented as a key operational feature.
Cons
- • The top customer accounted for Rs 3.66 crore (26.01 percent) of the company’s total sales for the period ended September 30, 2025; Rs 4.83 crore (30.21 percent) in FY25; Rs 1.26 crore (25.28 percent) in FY24, and Rs 0.44 crore (15.17 percent) in FY23. Any failure to retain this client or negotiate commercially viable long-term contracts, or a reduction in business from them, could adversely affect the company’s revenue, profitability, cash flows, and overall financial condition.
- • The top supplier accounted for Rs 5.57 crore (55.06 percent) of the company’s total purchase for the period ended September 30, 2025; Rs 4.01 crore (31.38 percent) in FY25; Rs 0.38 crore (9.68 percent) in FY24, and Rs 0.36 crore (13.55 percent) in FY23. Any inability to retain this vendor, negotiate commercially viable terms, or disruption in supplies from them could adversely affect the company’s operations, cost structure, and financial condition.
- • Gujarat accounted for Rs 13.54 crore (96.28 percent) of the company’s total sales for the period ended September 30, 2025; Rs 14.78 crore (92.34 percent) in FY25; Rs 4.12 crore (82.33 percent) in FY24, and Rs 2.43 crore (83.58 percent) in FY23. Furthermore, the company’s manufacturing facility is also located in this region. Any adverse political, social, regulatory, or economic developments in Gujarat, or an increase in local competition, could negatively impact the company’s business prospects, financial condition, and results of operations.
Get real-time IPO alerts on WhatsApp
Opening reminders • Subscription updates • GMP alerts • Allotment results
Start WhatsApp Alerts